Isolation, characterization, and biological evaluation of Syn and Anti diastereomers of [99mTc]technetium depreotide: A somatostatin receptor binding tumor imaging agent

Journal of Medicinal Chemistry

Volumn 50, Issue 18, 2007, Pages 4295-4303

  Cyr, John E ^a,d,e   Pearson, Daniel A ^a   Nelson, Carol A ^a   Lyons, Barbara A ^c   Zheng, Yongyong ^b   Bartis, Judit ^b   He, Jiafang ^b   Cantorias, Melchor V ^b   Howell, Robertha C ^b   Francesconi, Lynn C ^b  

^a Diatide   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d BAYER PHARMA AG   (Germany)

^e BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPREOTIDE TC 99M; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR BINDING TUMOR IMAGING AGENT; TECHNETIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG DISTRIBUTION; IC 50; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CIRCULAR DICHROISM; FEMALE; ISOTOPE LABELING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 34548474047     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060887v     Document Type: Article

References (44)

1. Reubi, J. C.; Kvols, L.; Krenning, E. W. L. S. Distribution of Somatostatin Receptors in Normal and Tumor Tissue. Metabolism 1990, 39 (9 Suppl 2), 78-81.
2. Bakker, W. H.; Krenning, E. P.; Breeman, W. A.; Koper, J. W.; Kooij, P. P.; Reubi, J.-C.; Klijn, J. G.; Visser, T. J.; Docter, R.; Lamberts, S. W. Receptor Scintigraphy with a Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals. J. Nucl. Med. 1990, 31, 1501.
3. Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.; Breeman, W. A. P.; Kooij, P. P. M.; Oei, H. Y.; van Hagen, M.; Postema, P. T. E.; deJong, M.; Reubi, J. E.; Visser, T. J.; Reijs, A. E. M.; Hofland, L. J.; Koper, J. W.; Lamberts, S. W. J. Somatostatin Receptor Scintigraphy with [111In-DTPA- D-Phe1]- and [123I-Tyr3]-Octreotide: The Rotterdam Experience with more than 1000 Patients. Eur. J. Nucl. Med. 1993, 20 (8), 716-731.
4. Breeman, W. A.; Hofland, L. J.; van der Pluijm, M.; van Koetsveld, P. M.; de Jong, M.; Setyono-Han, B.; Bakker, W. H.; Kwekkeboom, D. J.; Visser, T. J.; Lamberts, S. W. A New Radiolabeled Somatostatin Analogue [111In-DTPA-D-Phe1]RC160: Preparation, Biological Activity, Receptor Scintigraphy in Rats and Comparison with [111In-DTPA-D-Phe1]Octreotide. Eur. J. Nucl. Med. 1994, 21, 328-335.
5. Maecke, H. R.; Smith-Jones, P.; Maina, T.; Stolz, B.; Albert, R.; Bruns, C.; Reist, H. New Octreotide Deriviatives for In Vivo Targeting of Somatostatin Receptor-Positive Tumors for Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). Horm. Metab. Res. 1993, 27, 12-17.
6. Virgolini, I.; Szilvasi, I.; Kurtaran, A.; Angelberger, P.; Raderer, M.; Havlik, E.; Vorbeck, F.; Bischof, C.; Leimer, M.; Dorner, G.; Kletter, K.; Niederle, B.; Scheithauer, W.; Smith-Jones, P. Indium-111-DOTA-Lanreotide: Biodistribution, Safety and Radiation Absorbed Dose in Tumor Patients. J. Nucl. Med. 1998, 39, 1928-1936.
7. van der Lely, A. J.; deHerder, W. W.; Krenning, E. P.; Kwekkeboom, D. J. Octreoscan Radioreceptor Imaging. Endocrine 2003, 20 (3), 307-311.
8. Pearson, D. A.; Lister-James, J.; McBride, W. J.; Wilson, D. M.; Martel, L. J.; Civitello, E. R.; Taylor, J. E.; Moyer, B. R.; Dean, R. T. Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies. J. Med. Chem. 1996, 39, 1361-1371.
9. Virgolini, I.; Leimer, M. H. H.; Lastoria, S. C. B.; Muto, P.; Pangerl, T. D. G.; Peck-Radosavljevic, M.; Lister-James, J.; Hamilton, G.; Kaserer, K.; Valent, P.; Dean, R. T. Somatostatin Receptor Subtype Specificity and In Vivo Binding of a Novel Tumor Tracer, 99mTc-P829. Cancer Res. 1998, 58, 1850-1859.
10. Pauwels, E. K. J.; McCready, V. R.; Stoot, J. H. M. B.; van Deurzen, D. F. P. The Mechanism of Accumulation of Tumor-Localizing Radiopharmaceuticals. Eur. J. Nucl. Med. 1998, 25, 277-305 (review).
11. Virgolini, I.; Pangerl, T.; Bischof, C.; Smith-Jones, P.; Peck-Radosavljevic, M. Somatostatin Receptor Subtype Expression in Human Tissues: A Prediction for Diagnosis and Treatment of Cancer? Eur. J. Clin. Invest. 1997, 27, 645-647.
12. Blum, J. E.; Handmaker, H.; Rinne, N. A. The Utility of a Somatostatin-Type Receptor Binding Peptide Radiopharmaceutical (P829) in the Evaluation of Solitary Pulmonary Nodules. Chest 1999, 115, 224-232.
13. Handmaker, H.; Lister-James, J.; Baran, Y. M.; Abernathy, H. Scintigraphic Assessment of Hodgkin's and Non-Hodgkin Lymphoma Patients with a Novel SSTR Binding Peptide-Technetium Tc-99m P829. Radiology 1997, 205 (P), 478 (abstr).
14. Handmaker, H. Comparison of a Technetium Labeled SSTR Binding Peptide (P829) and Miraluma in the Diagnosis of Breast Cancer. J. Nucl. Med. 1998, 39, 315P (abstr).
15. Peller, P. J.; Khedkar, N. Y.; Martinez, C. J. Somatostatin Receptor Scintigraphy with Technetium-99m Peptide P829 Reveals Melanoma Metastases Not Detected by CT. J. Nucl. Med. 1999, 40, 254P (abstr).
16. Kurtaran, A.; Leimer, M.; Raderer, M.; Schima, W.; Smith-Jones, P.; Lister-James, J.; Virgolini, I. Somatostatin Receptor (SSTR) Scintigraphy (99mTc-P829) in the Clinical Management of Gastrointestinal Adenocarcinomas. J. Nucl. Med. 1999, 40, 244P (abstr).
17. Grummon, G.; Rajagopalan, R.; Palenik, G.; Koziol, A.; Nosco, D. Synthesis, Characterization, and Crystal Structures of Technetium-(V)-Oxo Complexes Useful in Nuclear Medicine. 1. Complexes of Mercaptoacetylglycylglycylglycine (MAG3) and Its Methyl Ester Derivative (MAG3OMe). Inorg. Chem. 1995, 34, 1764-1772.
18. Wong, E.; Fauconnier, T.; Bennett, S.; Valliant, J.; Nguyen, T.; Lau, F.; Lu, L.; Pollak, A.; Bell, R.; Thornback, J. Rhenium(V) and Technetium(V) Oxo Complexes of an N2N'S Peptidic Chelator: Evidence of Interconversion between the Syn and Anti Conformations. Inorg. Chem. 1997, 36, 5700-5708.
19. Wong, E.; Bennett, S.; Lawrence, B.; Fauconnier, T.; Lu, L. F. L.; Bell, R. A.; Thornback, J. R.; Eshima, D. Tuftsin Receptor-Binding Peptide Labeled with Technetium: Chemistry and Preliminary In Vitro Receptor-Binding Study. Inorg. Chem. 2001, 40, 5695-5700.
20. 99TcO] Apcitide: A Technetium Labeled Peptide. Inorg. Chem. 2004, 43, 2867-2875.
21. Cyr, J. E.; Nowotnik, D. P.; Pan, Y.; Gougoutas, J. Z.; Malley, M. F.; DiMarco, J.; Nunn, A. D.; Linder, K. E. Technetium(V) Oxo Complexes of Substituted Propylene Diamine Dioxime (PnAO) Ligands: Water-Dependent Interconversion between Syn and Anti Isomers. Inorg. Chem. 2001, 40, 3555-3561.
22. Cantorias, M. V.; Howell, R. C.; Todaro, L.; Cyr, J. E.; Berndorff, D.; Rogers, R. D.; Francesconi, L. C. MO Tripeptide Diastereomers (M = 99/99mTc, Re): Models to Identify the Structure of Peptide Targeted Radiopharmaceuticals. Inorg. Chem. 2007, in press.
23. Davison, A.; Trop, H.; DePamphilis, B.; Jones, A. Technetium Halides. Inorg. Synth. 1982, 21, 160.
24. DePamphilis, B. V.; Jones, A. G.; Davison, A. Ligand Exchange Reactivity Patterns of Oxotechnetium(V) Complexes. Inorg. Chem. 1983, 22, 2292-2297.
25. Boyd, G. Technetium and Promethium. J. Chem. Educ. 1959, 36, 3.
26. Epps, L. A.; Burns, H. D.; Lever, S. Z.; Goldfarb, H. W.; Wagner, H. N. Brain Imaging Agents: Synthesis and Characterization of (N-Piperidinylethyl) Hexamethyl Diaminodithiolate Oxo Technetium-(V) Complexes. Appl. Radiat. Isot. 1987, 38, 661-664.
27. Rao, T. N.; Adhikesavalu, D.; Camerman, A.; Fritzberg, A. R. Technetium(V) and Rhenium(V) Complexes of 2,3-Bis(mercaptoacetamido)propanoate. Chelate Ring Sterochemistry and Influence on Chemical and Biological Properties. J. Am. Chem. Soc. 1990, 112, 5798-5804.
28. Jurisson, S.; Schlemper, E. O.; Troutner, D. E.; Canning, L. R.; Nowotnik, D. P.; Neirinckx, R. D. Synthesis, Characterization, and X-ray Structural Determinations of Technetium(V)-Oxo-Tetradentate Amine Oxime Complexes. Inorg. Chem. 1986, 25, 543-549.
29. vO (M = Tc, Re) Amine-Thiol Complexes Containing a Pendant Phenylpiperidine Group. Inorg. Chem. 1993, 32 (14), 3114-3124.
30. Bell, R. A.; McCarry, B. E.; Valliant, J. F. The Synthesis, NMR Spectroscopy, and X-ray Structure of a New Rhenium N2S2 Chelate Complex. Inorg. Chem. 1998, 37, 3517-3520.
31. Taylor, J. E.; Magali, A. A. T. M.; Bashirzadem, R.; Reisine, T. A. E. P. Detection of Somatostatin Receptor Subtype 2 (SSTR2) in Established Tumors and Tumor Cell Lines: Evidence for SSTR2 Heterogeneity. Peptides. Peptides. 1994, 15, 1229-1236.
32. Patel, Y. C.; Srikant, C. B. Somatostatin Receptors. Trends Endocrinol. Metab. 1997, 8, 398-405.
33. Veber, D. F.; Saperstein, R. F. N. R.; Freidinger, R. M.; Brady, S. F.; Curley, P.; Perlow, D. S.; Paleveda, W. J.; Colton, C. D.; Zacchei, A. G.; Tocco, D. J.; Hoff, D. R.; Vandlin, R. L.; Gerich, J. E.; Hall, L.; Mandirino, L.; Cordes, E. H.; Anderson, P. S.; Hirschmann, R. A Super Active Cyclic Hexapeptide Analog of Somatostatin. Science 1984, 34, 1371-1378.
34. Kochman, K. A. G.; Kochman, H.; Kozlowski, H.; Masiukiewicz, E. B. R. Binding of Cu2+, Zn2+, and Ni(2+)-GnRH Complexes with the Rat Pituitary Receptor. J. Inorg. Biochem. 1997, 65, 277-279.
35. Giblin, M.; Wang, N.; Hoffman, T.; Jurisson, S.; Quinn, T. Design and Characterization of α-Melanotropin Peptide Analogs Cyclized through Rhenium and Technetium Metal Coordination. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12814-12818.
36. 1]-Octreotide, A Potential Radiopharmaceutical for Imaging of Somatostatin Receptor-Positive Tumors: Synthesis, Radiolabeling, and In Vitro Validation. Life Sci. 1991, 49, 1583-91.
37. 3]octreotide had a 6-fold better binding affinity than the uncomplexed ligand (complexed = 0.5 nM; uncomplexed = 3.0 nM): de Jong, M. Presentation at European Society of Nuclear Medicine Meeting, Barcelona, Spain, 1999. Abstract: de Jong, M.; Breeman, W. A. P.; Bernard, B. F.; van Gameren, A.; Schaar, M.; Bakker, W. H.; van der Pluijm, M. E.; Visser, T. J.; Maecke, H. R.; and Krenning, E. P. Tumor Uptake of the Radiolabeled Somatostatin Analog [DOTA-0, TYR-3]Octreotide is Dependent on the Peptide Amount. Eur. J. Nucl. Med. 1999, 26, abstract book 1026.
38. 3]octreotate: Reubi, J. C.; Schaer, J.-C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Maecke, H. R. Affinity Profiles for Human Somatostatin Receptor Subtypes SST1-SST5 of Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use. Eur. J. Nucl. Med. 2000, 27, 273-282.
39. 3]-octreotide vs AR42J tumor membranes = 2.44 and 2.37 nM, respectively: Heppeler, A.; Froidevaux, S.; Eberle, A. N.; Maecke, H. R. Receptor Targeting for Tumor Localization and Therapy with Radiopeptides. Curr. Med. Chem. 2000, 7, 971-994.
40. 1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy. Bioconjugate Chem. 2002, 13, 721-728.
41. Binding affinities for DOTA-AMBA and Lu-complexed peptide vs PC-3 cells = 4.75 and 2.50 nM, respectively: Lantry, L. E.; Cappelletti, E.; Maddalena, M. E.; Fox, J. S.; Feng, W.; Chen, J.; Thomas, R.; Eaton, S. M.; Bogdan, N. J.; Arunachalam, T.; Reubi, J. C.; Raju, N.; Metcalfe, E. C.; Lattuada, L.; Linder, K. E.; Swensen, R. E.; Tweedle, M. F.; Nunn, A. D. 177Lu-AMBA: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer. J. Nucl. Med. 2006, 47, 1144-1147.
42. Deshmukh, M. V.; Voll, G.; Kuehlewein, A.; Maecke, H.; Schmitt, J.; Kessler, H.; Gemmecker, G. NMR Studies Reveal the Structural Differences between the Gallium and Yttrium Complexes of DOTA-D-Phel-Tyr3-octreotide. J. Med. Chem. 2005, 48, 1506-1514.
43. Liu, S.; Edwards, D. S. Synthesis and Characterization of Two 111In-Labeled DTPA-Peptide Conjugates. Bioconjugate Chem. 2001, 12, 630-634.
44. Mahmood, A.; Jones, A. G. Technetium Radiopharmaceuticals. In Handbook of Radiopharmaceuticals; Welch, M. J., Redvanly, C. S., Eds.; John Wiley and Sons, Ltd.: West Sussex, England, 2003; pp 323-362.